Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

2.1K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.1K
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

1.8K
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
1.8K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

5.0K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
5.0K
Chronic Obstructive Pulmonary Disease I: Introduction01:23

Chronic Obstructive Pulmonary Disease I: Introduction

71
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
71
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

155
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
155
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations01:19

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

59
Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet...
59

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Atg5 deficiency alters myofibroblast accumulation and alveolar regeneration in lung fibrosis.

Stem cell reports·2026
Same author

Progenitor Resilience and the Early Onset of Chronic Lung Diseases: NHLBI workshop report.

American journal of respiratory cell and molecular biology·2026
Same author

Prognostic Value of Lung Injury Biomarkers in Patients Hospitalized With COVID-19 Without Respiratory Failure at Admission.

Critical care medicine·2026
Same author

Saving the lung from ozone pollutant: a new role of hyaluronan in alveolar regeneration.

American journal of respiratory cell and molecular biology·2026
Same author

Activation of the impaired NAMPT/SIRT7/SOD2 axis restores alveolar progenitor cell renewal in idiopathic pulmonary fibrosis.

The Journal of clinical investigation·2026
Same author

Immortalized AT2 Cell Lines from Healthy and IPF Lungs Enable 2D and 3D Cultures.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: May 5, 2026

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
03:38

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

1.1K

Pulmonary fibrosis: patterns and perpetrators.

Paul W Noble1, Christina E Barkauskas, Dianhua Jiang

  • 1Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. paul.noble@duke.edu

The Journal of Clinical Investigation
|August 2, 2012
PubMed
Summary
This summary is machine-generated.

Pulmonary fibrosis is a serious lung disease with varied forms. Differentiating these types, like connective tissue disease-related fibrosis from idiopathic pulmonary fibrosis (IPF), is crucial for effective treatment development.

More Related Videos

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

2.2K
Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

1.4K

Related Experiment Videos

Last Updated: May 5, 2026

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
03:38

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

1.1K
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

2.2K
Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

1.4K

Area of Science:

  • Pulmonology
  • Pathology
  • Immunology

Background:

  • Pulmonary fibrosis is a significant cause of illness and death, with limited treatment options.
  • The heterogeneity of fibrosing lung diseases complicates accurate diagnosis and treatment strategies.
  • Connective tissue disease-associated pulmonary fibrosis may respond to immunosuppression, unlike idiopathic pulmonary fibrosis (IPF).

Purpose of the Study:

  • To highlight the critical need for understanding the heterogeneity of fibrosing lung diseases.
  • To emphasize the importance of distinguishing between different forms of pulmonary fibrosis for targeted therapies.
  • To underscore the necessity of identifying common fibrogenesis pathways for developing effective treatments.

Main Methods:

  • Review of existing literature on pulmonary fibrosis classification and treatment.
  • Analysis of pathological differences between various fibrosing lung conditions.
  • Evaluation of animal models for their relevance to human fibrotic lung diseases.

Main Results:

  • Pulmonary fibrosis presents heterogeneously, impacting treatment efficacy.
  • Idiopathic pulmonary fibrosis (IPF) is distinct from other fibrotic lung diseases and resistant to immunomodulatory therapies.
  • Animal models, while imperfect, offer insights into potential therapeutic targets for fibrosis.

Conclusions:

  • Accurate differentiation of fibrosing lung disease subtypes is essential for advancing patient care.
  • Elucidating the final common pathways of fibrogenesis is key to developing novel therapies.
  • Addressing the unmet medical need in pulmonary fibrosis requires a deeper understanding of disease heterogeneity.